CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于 CAR-T 细胞治疗的原代小鼠 T 细胞扩增与逆转录病毒转导
英文原题：Expansion and Retroviral Transduction of Primary Murine T Cells for CAR T-Cell Therapy.
查看英文原题
Expansion and Retroviral Transduction of Primary Murine T Cells for CAR T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞的开发，是治疗复发/难治性白血病及淋巴瘤的一项革命性技术。合成CAR分子通过一个与CD3ζ及胞内共刺激结构域融合的单链可变片段（scFv），将T细胞功能重新导向肿瘤表面表达的抗原。本文介绍一种利用原代小鼠T细胞和编码CAR转基因的γ逆转录病毒载体制备CAR-T 细胞的方案。方案概述了多种转导和扩增方法，包括使用两种转导增强剂RetroNectin和Vectofusin-1，以及采用常规培养板或G-Rex装置等细胞培养系统。
展开英文摘要原文
The development of chimeric antigen receptor (CAR) T cells has been a revolutionary technology for the treatment of relapsed and refractory leukemias and lymphomas. The synthetic CAR molecule redirects T cell function toward tumor surface-expressed antigens through a single-chain variable fragment (scFv) fused to CD3z and intracellular costimulatory domains.
Here, we describe a protocol for the generation of CAR T cells using primary mouse T cells and a gammaretroviral vector encoding a CAR transgene. This protocol outlines several transduction and expansion methods based on the use of two transduction enhancers, RetroNectin and Vectofusin -1, and cell culture systems such as conventional plates or G-Rex devices.
论文信息
- 作者
- Loos P、Short L、Savage G、Evgin L
- 第一作者单位
- Michael Smith Genome Sciences Department, BC Cancer Research Institute, Vancouver, BC, Canada.Canada
- 通讯作者单位
- Michael Smith Genome Sciences Department, BC Cancer Research Institute, Vancouver, BC, Canada. levgin@bcgsc.ca.Canada
- 文献类型
- 非美国政府资助研究
- 期刊
- Methods in molecular biology (Clifton, N.J.)2024
- 原文标识
- PubMed 38070106 · DOI 10.1007/978-1-0716-3593-3_4